GCG and Hyperglycemia: Because the magnitude and duration of hyperglycaemia required to attenuate the insulinotropic effect of GIP appears to be relatively modest, future evaluation of the use of incretin-based approaches in the critically ill patient should focus on GLP-1 and its agonists.